DetermaIO Publications and Abstracts


Antoniotti C, Boccaccino A, Seitz R, et al. (2023). An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer. Clin Cancer Res CCR-22-3878. View Article

Iwase T, Blenman K, Li X, et al. (2021). A Novel Immunomodulatory 27-Gene Signature to Predict Response to Neoadjuvant Immunochemotherapy for Primary Triple-Negative Breast Cancer. Cancers 13(19):4839. – View Article

Nielsen T, Ring B, Seitz R, et al. (2021). A novel immuno-oncology algorithm measuring tumor microenvironment to predict response to immunotherapies. Heliyon 7(3):e06438. View Article

Nielsen T, Varga M, Cronister C, et al. (2023). The 27-gene IO score is associated with efficacy of PD-1/L1 inhibitors independent of FGFR expression in a real-world metastatic urothelial carcinoma cohort. Cancer immunology, immunotherapy: CII, 10.1007/s00262-023-03401-x. View Article

Page D, Pucilowska J, Chun B, et al. (2023). A phase Ib trial of pembrolizumab plus paclitaxel or flat-dose capecitabine in 1st/2nd line metastatic triple-negative breast cancer. NPJ Breast Cancer 9(1):53. – View Article

Ranganath H, Jain A, Smith J, et al. (2022). Association of a novel 27-gene immuno-oncology assay with efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer. BMC cancer 22:407. – View Article

Saltman D, Nielsen T, Salina D, et al. (2021). Characterization of the tumor immune-microenvironment of adenocarcinoma of lung with a metastatic lesion in the pancreas treated successfully with first-line, single-agent pembrolizumab. Ther Adv Med Oncol 13:17588359211010156. – View Article

Saltman D, Varga M, Nielsen T, et al. (2023). 27-gene Immuno-Oncology (IO) Score is Associated With Efficacy of Checkpoint Immunotherapy in Advanced NSCLC: A Retrospective BC Cancer Study. Clin Lung Cancer 24(2):137-144. View Article

Seitz R, Hurwitz M, Nielson T, et al. (2022). Translation of the 27-gene immuno-oncology test (IO score) to predict outcomes in immune checkpoint inhibitor treated metastatic urothelial cancer patients. J Transl Med 20:370. – View Article

Spring L, Bar Y, Isakoff S. (2022). The Evolving Role of Neoadjuvant Therapy for Operable Breast Cancer. J Natl Compr Canc Netw 20(6):723-734. – View Article

Posters & Abstracts

Bianchini G, Dugo M, Huang C, et al. (2021) . Predictive value of gene-expression profiles (GEPs) and their dynamics during therapy in the NeoTRIPaPDL1 trial. ESMO Congress, Abstract LBA12, Lugano, Switzerland.

View Abstract

Dugo M, Huang C, Egle D, et al. (2021). Predictive value of RT-qPCR 27-gene IO score and comparison with RNA-Seq IO score in the NeoTRIPaPDL1 trial. San Antonio Breast Cancer Symposium, Abstract PD10-06, San Antonio, TX.

View Abstract | View Poster

Iwase T, Pusztai L, Blenman K, et al. (2020). Validation of an immunomodulatory gene signature algorithm to predict response to neoadjuvant immunochemotherapy in patients with primary triple-negative breast cancer. ASCO Annual Meeting I, Abstract 3117.

View Abstract | View Poster

Nielsen T, Varga M, McGregor K, et al. (2021). CD274 (PD-L1) gene expression and the 27-gene immuno-oncology (IO) assay are associated with efficacy to immune checkpoint inhibitor treated patients with non-small cell lung cancer. SITC Annual Meeting, Abstract 5.

View Abstract | View Poster

Nielsen T, Seitz S, Varga M, et al. (2022). Confirmatory study of the IO Score, a tumor immune microenvironment (TIME) classifier, demonstrates efficacy in a real-world cohort of metastatic urothelial cancer (mUC) patients treated with immune checkpoint inhibitors (ICIs). AACR Annual Meeting, Abstract 1272, New Orleans, LA.

View Abstract | View Poster

Nielsen T, McMahon F, Spille J, et al. (2020). Predicting Response to Immunotherapies Using Minimal Tissue: A Novel 27-Gene Immuno-Oncology Assay that Measures the Tumor Microenvironment. AMP Annual Meeting, Abstract 915449.

View Poster

Seitz R, Nielsen T, Ring B, et al. (2023). The 27-gene IO score is associated with pathologic complete response (pCR) in HR+/HER2- breast cancer patients treated with pembrolizumab in the I-SPY2 Trial. AACR Annual Meeting, Abstract P5-02-26.

View Abstract | View Poster

Seitz R, Nielsen T, Schweitzer B, et al. (2021). Pathway modeling to translate the 27-gene immuno-oncology algorithm into bladder cancer. AACR Annual Meeting, Abstract 175.

View Abstract | View Poster | View Video of Explanation

Seitz R, Ross D, Nielsen T, et al. (2021). Validation of a 27-gene immuno-oncology algorithm in metastatic urothelial carcinoma treated with an immune checkpoint inhibitor. AACR Annual Meeting, Abstract 23.

View Abstract | View Presentation | View Video of Presentation

Sharma P, Stecklein S, Yoder R, et al. (2022). Clinical and biomarker results of neoadjuvant phase II study of pembrolizumab and carboplatin plus docetaxel in triple-negative breast cancer (TNBC) (NeoPACT). ASCO Annual Meeting I, Abstract 513, Chicago, IL.

View Abstract

Varga M, Nielsen T, Vidal G, et al. (2021). A 27-gene IO assay to capture the tumor immune microenvironment is associated with response in metastatic and primary tumors. IASLC World Conference on Lung Cancer, Abstract P60.10.

View Abstract | View Poster

Varga M, Cronister C, Nielsen T, et al. (2022). The 27-gene IO score is associated with molecular features and response to immune checkpoint inhibitors (ICI) in patients with gastric cancer. ASCO Annual Meeting I, Abstract 4058, Chicago, IL.

View Abstract | View Poster

Thanks for your interest in